



**Company Contact:**  
Jie Du, Ph.D.  
President & CEO  
JDP THERAPEUTICS, INC.  
Email: [jjedu@jdptherapeutics.com](mailto:jjedu@jdptherapeutics.com)  
[www.jdptherapeutics.com](http://www.jdptherapeutics.com)

## **JDP Announces Appointment of Chief Business Officer**

**LANSDALE, PENNSYLVANIA, February 6, 2012, 2012** – JDP Therapeutics Inc., a privately held specialty pharmaceutical company, today announced that Sharon Clarke has joined JDP Therapeutics as its Chief Business Officer. This appointment comes after Ms. Clarke serving as JDP's Commercial/Business Advisor since Sept 2011. Ms. Clarke brings a wealth of Pharmaceutical experience expanding more than twenty years in General Management and leading commercial groups in pharma companies including Wallace Laboratories, MedPointe Pharmaceuticals and Meda Pharmaceuticals. Prior to joining JDP Therapeutics, Ms. Clarke led Meda Pharmaceuticals, the US division of MEDA AB, as President and General Manager. Ms. Clarke holds a degree in Microbiology and Chemistry from East Tennessee State University.

"We are delighted to have Ms. Clarke join us as our Chief Business Officer", said Jie Du, Ph.D., President and CEO at JDP Therapeutics. "Sharon's deep pharmaceutical commercial expertise combined with her extensive leadership experience, represents a significant addition to our organization's capabilities. With Sharon's addition to our team, we have great confidence in our ability to execute on our aggressive growth objectives. We welcome Sharon to the CBO role in the Company and look forward to her contribution to the future development of JDP".

### **About JDP Therapeutics Inc.**

JDP Therapeutics Inc. is a privately held, clinical stage specialty pharmaceutical company focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use of acute care in the hospital setting.

JDP Therapeutics pursues unfulfilled opportunities in existing molecules from which it develops unique dosage forms, novel formulations, and new indications to achieve full therapeutic and market potential. This approach mitigates risk, shortens development cycle, leads to a well-defined regulatory pathway, and fully characterizes clinical needs for each product opportunity.

For further information, please email [info@jdptherapeutics.com](mailto:info@jdptherapeutics.com)

###

#### *Safe Harbor Statement Regarding Forward-looking Statements*

*The statements in this release and oral statements made by representatives of JDP relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research or clinical trials, any market that might develop for any of JDP's product candidates are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of JDP and/or its partners to develop, manufacture and commercialize, JDP's ability to fund such efforts with or without partners, and other risks.*